Weight Loss Treatments
4 articles on Weight Loss Treatments, written by Shotlee and medically reviewed for clinical accuracy.
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Duodenal Resurfacing: A New Hope Beyond GLP-1 Weight Loss?
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
7 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
Obesity Medications: How They Might Transform the GLP-1 Sector
The GLP-1 market, initially dominated by weekly injections, is entering a new phase with the introduction of obesity pills. These oral options from Novo Nordisk and Eli Lilly promise greater convenience and possibly lower costs, attracting new users and reshaping the industry. Analysts predict significant market growth, with pills capturing a substantial share by 2030.
9 min read